We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Protein Kinase A (PKA)

Protein kinase A (PKA) inhibitors and activators act on the main kinase that relays cyclic nucleotide signals in cells. PKA was described in 1968 as an adenosine 3',5'-monophosphate-dependent protein kinase from rabbit skeletal muscle. The inactive enzyme is a tetramer of two regulatory and two catalytic subunits, and cyclic adenosine monophosphate (cAMP) binding releases the catalytic subunits. H 89 2HCl is a salt of H-89, an isoquinolinesulfonamide inhibitor reported in 1990. PKI 14-22 amide, myristoylated, is a cell-permeable peptide derived from the endogenous protein kinase inhibitor. Bucladesine sodium, a dibutyryl cAMP analog, activates PKA in intact cells instead. AT13148 inhibits PKA along with related kinases such as Akt, and further relatives are listed under Protein Kinase C (PKC).

4 Items

  • Rp-cAMPS sodium salt
    Cat. No.
    A37151
    CAS No.
    142439-94-9

    Rp-cAMPS sodium salt

    Rp-cAMPS sodium salt is a selective antagonist of protein kinase A (PKA) I and II, acting through competitive inhibition of cAMP-induced activation, with inhibition constants (Kis) of 12.5 µM and 4.5 µM, respectively. This stable cAMP analog is resistant to phosphodiesterase hydrolysis, making it an essential tool for investigating PKA signaling pathways. Rp-cAMPS sodium salt is widely utilized in cellular and biochemical research applications where modulation of PKA activity is required.

    In stock View Details
    1 mg
    $145.00
    5 mg
    $245.00
    All 6 sizes
  • Rp-8-CPT-cAMPS sodium
    Cat. No.
    A37176
    CAS No.
    221905-35-7

    Rp-8-CPT-cAMPS sodium

    Rp-8-CPT-cAMPS sodium is a competitive antagonist of cAMP, specifically inhibiting the activation of protein kinase A (PKA) types I and II. It demonstrates preferential binding to site A of the regulatory subunit RI and site B of the regulatory subunit RII, making it a valuable tool for dissecting cAMP signaling pathways. This compound is widely utilized in research focused on intracellular signaling, pharmacology, and the role of PKA in various physiological processes.

    In stock View Details
    0.5 mg
    $360.00
    1 mg
    $690.00
    All 2 sizes
  • Rp-8-CPT-cAMPS
    Cat. No.
    A37181
    CAS No.
    129735-01-9

    Rp-8-CPT-cAMPS

    Rp-8-CPT-cAMPS is a potent antagonist of cAMP-dependent protein kinase A (PKA), inhibiting the activation of both PKA I and II. This cAMP analog selectively targets site A of the regulatory subunit type I over site A of type II, as well as site B of type II over site B of type I. Its ability to modulate PKA activity makes it a valuable tool for investigating downstream signaling pathways influenced by cAMP. Researchers can utilize Rp-8-CPT-cAMPS in studies focused on cellular responses and signal transduction mechanisms.

    In stock View Details
    5 mg
    $795.00
    All 1 sizes
  • Rp-cAMPS
    Cat. No.
    A37193
    CAS No.
    73208-40-9

    Rp-cAMPS

    Rp-cAMPS is a potent antagonist of cyclic adenosine monophosphate (cAMP) that effectively inhibits the activation of protein kinase A (PKA) types I and II, exhibiting Ki values of 12.5 µM and 4.5 µM, respectively. This cAMP analog is resistant to hydrolysis by phosphodiesterases, making it suitable for research focused on cAMP signaling pathways. Rp-cAMPS is commonly used in studies investigating the regulatory role of PKA in various physiological processes and disease models.

    In stock View Details
    1 mg
    $335.00
    All 1 sizes

4 Items

Added to your cart

View Cart Checkout

    Loading...